Table 1.
Outcome results in main studies on elderly APL
| Author | Year | N°Pts | Relapse risk | Median age (yrs) | Induction | Consolidation | CR (%) | OS (%) | DFS (%) |
|---|---|---|---|---|---|---|---|---|---|
| Mandelli | 2003 | 86 | Low nr Int nr High 16% |
65.8 | ATRA + Ida | 3 cycles | 86 | 56 (6 yrs) | 59 (6 yrs) |
| Sanz | 2004 | 104 | Low 37% Int 43% High 20% |
68.0 | ATRA + Ida | 3 cycles | 84 | NR | 79 (6 yrs) |
| Ades | 2005 | 129 | Low nr Int nr High 0% |
66.0 | ATRA + Dauno+ AraC | 2 cycles | 86 | 57.8 (4 yrs) | 53 (4 yrs) |
| Latagliata | 2011 | 60 | Low 34.6% Int 51.9% High 13.5% |
66.1 | ATRA + Ida | 1 cycle | 90 | 68.5 (5 yrs) | 64.6 (5 yrs) |
| Ono | 2012 | 46 | Low 28% Int 52% High 20% |
63.0 | ATRA + Ida- AraC | 3 cycles | 89 | 63 (10 yrs) | 65 (10 yrs) |
| Lengfelder | 2013 | 56 | Low 27% Int 42% High 31% |
67.0 | ATRA + TAD | 1 cycle | 82 | 45 (7 yrs) | 48% (7 yrs) |
Legend: ATRA, All-trans retinoic acid. Ida, idarubicin. AraC, cytosine arabinoside. TAD, thioguanine, cytocine arabinoside, daunorubicin. CR, complete remission. OS, overall survival. DFS, disease-free survival. Nr= not reported